Vaccine RNA-peptide against SARS-CoV-2 with endogenous exosomes as carrier
AssigneeElidan America, LLC.
InventorLuis Cruz Rodriguez
Life of this patent
Estimating the term…
Abstract
A vaccine RNA-peptide against SARS-CoV-2, which has a messenger ribonucleic acid (mRNA) having an open reading frame encoding a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein. The peptide of the severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein is fused to a synthetic poly ADP-ribose polymerase peptide. The vaccine RNA-peptide against SARS-CoV-2 has endogenous exosomes as carrier.
Claims14
A composition against SARS-CoV-2, comprising a micro ribonucleic acid (miRNA) fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein having an amino acid sequence of SEQ ID NO:
- 2 wherein endogenous exosomes act as carrier.
A composition against SARS-CoV-2, comprising a micro ribonucleic acid (miRNA) fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein having the amino acid sequence of SEQ ID NO:
- 2 fused to a synthetic poly ADP-ribose polymerase peptide.
A composition against SARS-CoV-2 comprising a micro ribonucleic acid (miRNA) having a nucleic acid sequence of SEQ ID NO:
- 1 fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein fused to a synthetic poly ADP-ribose polymerase peptide that comprises the amino acid sequence of SEQ ID NO:
- 4, wherein endogenous exosomes act as carrier.
Dependencies are inferred from the claim text.